Experic announced a strategic collaboration with Flurry Powders to bring together complementary expertise to accelerate development of next‑generation therapies requiring advanced particle engineering.
Under the collaboration, Flurry will support Experic’s clients with specialized spray drying, formulation development, particle engineering, and analytical capabilities. A central advantage of the partnership is that Experic operates the only GMP spray dryer configured to Flurry’s proprietary PSD‑1 specifications, which have demonstrated 15–20% increases in lung dose relative to conventional PSD‑1 scale dryers. This unique relationship enables efficient process transfer from R&D to GMP manufacturing without compromising performance or risking extended timelines.
This collaboration unlocks significant opportunities for developing challenging molecules, including lipophilic, waxy, and poorly aqueous-soluble APIs, as well as sensitive biologics that can be stabilized as dry powders.
“Partnering with Flurry Powders expands the solutions we offer developers advancing inhaled and nasal therapies. By integrating spray-drying innovation with GMP manufacturing, we enable clients to reduce risk, accelerate timelines, and bring high-performing powder-based products into the clinic,” said Matthew Mollan, CEO of Experic.
“Experic’s spray-drying capabilities, aligned with our PSD-1 system, create a seamless bridge from R&D to clinical manufacturing. Together, we enable innovators to advance complex inhalation and nasal products with greater confidence and performance,” said Andreas Boeckl, Founder and CEO of Flurry Powders.